# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Diagnostics Advisory Committee (DAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** 22 June 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Brian Shine (Chair for second topic) Present for items 1 to 2.1.6 and 3 to 3.5.3
2. Ghada Ahmed Present for items 1 to 2.2.3
3. Keith Abrams Present for all items
4. Rebecca Allcock Present for items 1 to 2.2.3
5. John Cairns Present for all items
6. Sam Creavin Present for all items
7. Diane Davies Present for all items
8. Rashmi Kumar Present for all items
9. Brendan Meyer Present for all items
10. Neil Hawkins (Chair for first topic) Present for all items
11. Matt Stevenson Present for items 1 to 2.1.6 and 3 to 3.5.3
12. Anne Scott Present for all items
13. Jonathan Weir-McCall Present for all items

**Specialist committee members present**

Caroline Addison, Consultant Clinical Scientist, Present for items 1 to 2.2.3  
Gateshead Health NHS Foundation Trust

Mary Craig, GP Cancer Lead, Aneurin Bevan Present for items 1 to 2.2.3  
University Health Board

Farhat Din, Senior Lecturer and Consultant Colorectal Present for items 1 to 2.2.3  
Surgeon, Western General Hospital, Edinburgh

Michael Gray, Lay specialist committee member Present for items 1 to 2.2.3

John Morris, Lay specialist committee member

Brian Nicholson, GP and Clinical Lecturer, University of Oxford Present for items 1 to 2.1.6

Edward Seward, Consultant Gastroenterologist, University Present for items 1 to 2.2.3  
College London Hospitals NHS Foundation Trust

Baljit Singh, Consultant Colorectal Surgeon and Honorary Present for items 1 to 2.2.3  
Associate Professor, University Hospitals of Leicester NHS Trust

James Stephenson, Consultant Radiologist, University Hospitals Present for items 1 to 2.2.3  
of Leicester NHS Trust

Robin Alcock, Consultant Radiologist, Salisbury District Hospital Present for items 3 to 3.5.3  
Alberto Alonso, Consultant Thoracic Radiologist, Manchester Present for items 3 to 3.5.3  
University NHS FT Hospital, Sheffield

Fergus Gleeson, Professor of Radiology, Consultant Present for items 3 to 3.4.5  
Radiologist, Oxford University Hospitals

Emma O’Dowd, Consultant Respiratory Physician, Present for items 3 to 3.5.3  
Nottingham City Hospitals

Alan Thomas, Lay specialist committee member Present for items 3 to 3.5.3

Ian Woolhouse, Consultant Respiratory Physician, Queen Present for items 3 to 3.5.3  
Elizabeth Hospital Birmingham

External assessment group representatives present

Matt Stevenson, Professor of Health Technology Assessment, Present for items 1 to 2.1.6  
School of Health and Related Research (ScHARR),   
The University of Sheffield

Sue Harnan, Senior Research Fellow, ScHARR Present for items 1 to 2.1.6

Aline Navega Biz, Research Fellow, ScHARR Present for items 1 to 2.1.6

Jean Hamilton, Research Fellow, ScHARR Present for items 1 to 2.1.6

Susan O'Connell, Principal Researcher, Present for items 3 to 3.4.5

Cedar Health Technology Research Centre

Michael Beddard, Senior Researcher, Present for items 3 to 3.4.5

Cedar Health Technology Research Centre

Chris Stinton, Senior Research Fellow, Warwick Evidence Present for items 3 to 3.4.5

Mary Jordan, Research Fellow, Warwick Evidence Present for items 3 to 3.4.5

NICE staff present

Sarah Byron, Programme Director Present for all items

Rebecca Albrow, Associate Director, Diagnostics Assessment Present for all items

Programme (DAP)

Frances Nixon, Health Technology Assessment Adviser, DAP Present for all items

Judith Shore, Health Technology Assessment Adviser, DAP Present for items 1 to 2.2.3

Jacob Grant, Health Technology Assessment Analyst, DAP Present for items 1 to 2.2.3

Alice Bell, Associate Health Technology Assessment Analyst Present for items 3 to 3.5.3  
DAP

Thomas Lawrence, Data Scientist, Managed Access Present for items 3 to 3.5.3

Anne Murray-Cota, Senior Analyst – Data and Analytics (SEA) Present for items 3 to 3.5.3

Toni Gasse, Project Manager, DAP Present for all items

Alex Sexton, Administrator, DAP Present for all items

Observers present

Omnia Bilal, Technical Analyst, NICE Present for items 1 to 2.1.6 and 3 to 3.5.3

## Sarah Bromley, Senior Medial Editor, NICE Present for items 3 to 3.5.3

Matthew Brown, Digital Media Manager, NICE Present for all items

Lyn Davies, Coordinator, Meetings in Public, NICE Present for items 1 to 2.1.6 and 3 to 3.4.5

Hayley Garnett, Senior Medical Editor, NICE Present for items 1 to 2.2.3

## Benjamin Gregory, Resource Impact, NICE Present for items 3 to 3.5.3

Emily Henderson, Content Editor, NICE Present for items 1 to 2.2.3

Suzie Panek, Resource Impact, NICE Present for items 1 to 2.2.3

Louisa Robinson, HTA Analyst, NICE Present for items 1 to 2.2.3

Janine Wigmore, Public Involvement Adviser, NICE Present for all items

## Minutes

1. Introduction to the meeting
   1. The Chair welcomed members of the committee and other attendees present to the meeting.
   2. The Chair noted apologies from Patrick McGinley, Radha Ramachandran, and Karen Sennett. He further noted that Joy Allen and Michael Messenger were not attending due to conflicts of interest, and that Matt Stevenson was attending as a member of the External Assessment Group for part 1 only.
2. Appraisal of Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care
   1. Part 1 – Open session
      1. The Chair welcomed external assessment group (EAG) representatives, members of the public, and company representatives from Abbott, Aidan, Alpha Labs, Biohit, Mast Group Ltd, Sentinel and UNA Health.
      2. The Chair asked all committee members and specialist committee members to declare any new relevant interests in relation to the topic being considered in addition to those declared in advance of the meeting. A register of interests for committee and specialist committee members can be found on the NICE web page for this assessment: <https://www.nice.org.uk/guidance/indevelopment/gid-dg10036/consultation/html-content>
      3. The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of the ‘Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care’ assessment. The Committee was asked if there were any specific equality issues to consider in relation to this assessment.
      4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
      5. The Chair thanked the company representatives, public observers and the External Assessment Group for their attendance at the meeting.
      6. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and the company representatives, public observers and External Assessment Group left the meeting.
   2. Part 2 - Closed session
      1. The committee discussed confidential information submitted for this item.
      2. The committee discussed next steps.
      3. The committee asked the NICE technical team to prepare the Draft Guidance in line with their decisions.
3. Appraisal of Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals
   1. The Chair welcomed members of the committee and other attendees present to the meeting.
   2. The Chair noted apologies from Ghada Ahmed, Rebecca Allcock, Patrick McGinley, Radha Ramachandran, and Karen Sennett. He further noted that Joy Allen and Michael Messenger were not attending due to conflicts of interest. Apologies were also noted from specialist committee member Christopher Johns.
   3. Rebecca Albrow noted that the topic had been routed into the Early Values Assessments (EVAs) pilots. EVAs are trialling a new approach to assessing those technologies that most reflect system need and demand, taking an initial look at technologies to provide an assessment of early value. This was the first EVA to come back to a second committee meeting, to address consultation comments.
   4. Part 1 – Open session

The Chair welcomed external assessment group (EAG) representatives, members of the public, and company representatives from Annalise.ai, Behold.ai, InferVision UK Ltd, Lunit and Siemens Healthineers.

* + 1. The Chair asked all committee members and specialist committee members to declare any new relevant interests in relation to the topic being considered in addition to those declared in advance of the meeting. A register of interests for committee and specialist committee members can be found on the NICE web page for this assessment: <https://www.nice.org.uk/guidance/indevelopment/gid-hte10018>
    2. The Committee proceeded to discuss the comments made during the public consultation for the ‘Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals’ topic and additional analyses. The Committee was asked if there were any specific equality issues to consider in relation to this assessment.
    3. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
    4. The Chair thanked the company representatives, public observers and the External Assessment Group for their attendance at the meeting.
    5. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and the company representatives, public observers and External Assessment Group left the meeting.
  1. Part 2 - Closed session
     1. The committee discussed confidential information submitted for this item.
     2. The committee discussed next steps.
     3. The committee asked the NICE technical team to prepare the Early Value Document in line with their decisions.